| Poor outcomes associated with+ der (22) t (9; 22) and− 9/9p in patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia receiving chemotherapy plus a … NJ Short, HM Kantarjian, K Sasaki, F Ravandi, H Ko, C Cameron Yin, ... American journal of hematology 92 (3), 238-243, 2017 | 50 | 2017 |
| Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma NJ Short, HM Kantarjian, H Ko, JD Khoury, F Ravandi, DA Thomas, ... American journal of hematology 92 (6), E114, 2017 | 45 | 2017 |
| Hemolytic uremic syndrome associated with Escherichia coli O157:H7 infection in older adults: a case report and review of the literature H Ko, H Maymani, C Rojas-Hernandez Journal of Medical Case Reports 10, 1-4, 2016 | 38 | 2016 |
| Clinical utility of 18F-FDG PET/CT in staging localized breast cancer before initiating preoperative systemic therapy H Ko, Y Baghdadi, C Love, JA Sparano Journal of the National Comprehensive Cancer Network 18 (9), 1240-1246, 2020 | 31 | 2020 |
| Predictors of survival in patients with advanced gastrointestinal malignancies admitted to the intensive care unit H Ko, M Yan, R Gupta, K Kebbel, A Maiti, J Song, J Nates, MJ Overman The oncologist 24 (4), 483-490, 2019 | 12 | 2019 |
| Older age and increased neutrophil-to-lymphocyte ratio (NLR) are predictors of mortality in a multiethnic urban cohort of hematologic neoplasms and COVID-19 patients A D'Aiello, S Zareef, K Pradhan, A Lombardo, F Khatun, J Mustafa, ... Blood 136, 34-35, 2020 | 6 | 2020 |
| The impact of single gene testing (SGT) on subsequent comprehensive genomic profiling (CGP) success in community oncology practice for advanced non-small cell lung cancer … MK Nesline, P DePietro, M Cooper, S Zhang, S Howarth, ZD Wallen, ... Journal of Clinical Oncology 41 (16_suppl), 6506-6506, 2023 | 2 | 2023 |
| Abstract PS4-30: Neutrophil-to-lymphocyte ratio or platelet-to-lymphocyte ratio as prognostic biomarkers in patients with metastatic breast cancer treated with CDK4/6 inhibitors A Weiner, LS Munoz-Arcos, H Ko, J Anampa Cancer Research 81 (4_Supplement), PS4-30-PS4-30, 2021 | 2 | 2021 |
| Clinical utility of 18F-FDG-PET/CT in staging localized breast cancer prior to initiating preoperative systemic therapy. H Ko, Y Baghdadi, C Love, JA Sparano Journal of Clinical Oncology 38 (15_suppl), 563-563, 2020 | 2 | 2020 |
| Clinical outcomes of acquired factor VIII inhibitors in cancer population: a systematic review HC Ko, C Rojas Hernandez, TH Oo Blood 130 (Supplement 1), 5639-5639, 2017 | 2 | 2017 |
| LAG3 landscape in solid tumors and its association with immunotherapy outcomes in non-small cell lung cancer. R Seager, MF Senosain, E Van Roey, S Gao, P DePietro, MK Nesline, ... Journal of Clinical Oncology 41 (16_suppl), e21113-e21113, 2023 | 1 | 2023 |
| A machine learning algorithm based on multi-omics biomarkers for the detection of tumor microsatellite instability. KC Strickland, S Pabla, ZD Wallen, MK Nesline, HC Ko, RA Previs, ... Journal of Clinical Oncology 42 (16_suppl), 1554-1554, 2024 | | 2024 |
| Interaction between VEGF-A and immune checkpoint targets in triple-negative breast cancer and mechanisms of immune evasion and tumor progression. RJ Seager, S Pabla, S Gandhi, MF Senosain, H Parikh, E Van Roey, ... Journal of Clinical Oncology 42 (16_suppl), 1096-1096, 2024 | | 2024 |
| Evaluating tumor inflammation and PD-L1 expression in sequential biopsies of real-world primary and metastatic breast cancer. ZD Wallen, S Pabla, MK Nesline, S Gao, E Vanroey, P DePietro, ... Journal of Clinical Oncology 42 (16_suppl), e13035-e13035, 2024 | | 2024 |
| Comprehensive genomic and immune profiling of non-V600 BRAF-mutated melanomas: Implications for therapeutic strategies beyond BRAF/MEK inhibitors. MF Senosain, S Pabla, RJ Seager, E Van Roey, S Gao, H Parikh, ... Journal of Clinical Oncology 42 (16_suppl), e21544-e21544, 2024 | | 2024 |
| Novel HLA-Ilo/HLA-IIhi phenotype and immune evasion in triple-negative breast cancer. HC Ko, RJ Seager, S Gandhi, MF Senosain, H Parikh, E Van Roey, S Gao, ... Journal of Clinical Oncology 42 (16_suppl), 1095-1095, 2024 | | 2024 |
| Pervasive loss of antigen presentation in solid tumors driven by loss of HLA class I expression. S Pabla, HC Ko, MF Senosain, H Parikh, RJ Seager, E Van Roey, S Gao, ... Journal of Clinical Oncology 42 (16_suppl), e14654-e14654, 2024 | | 2024 |
| Phase II study of the combination of lenvatinib (L) and eribulin (E) in advanced solid tumors. RS Banwait, HC Ko, J Michalek, KI Lathrop, EA Bowhay-Carnes, ... Journal of Clinical Oncology 42 (16_suppl), 3158-3158, 2024 | | 2024 |
| Abstract PO5-06-09: Metastatic triple negative breast cancer has distinct tumor immune landscape R Seager, H Ko, S Pabla, MF Senosain, E Van Roey, S Gao, K Strickland, ... Cancer Research 84 (9_Supplement), PO5-06-09-PO5-06-09, 2024 | | 2024 |
| Abstract PO4-25-03: Comprehensive immune profiling reveals factors associated with neoadjuvant chemotherapy response in triple negative breast cancer R Seager, H Ko, S Pabla, MF Senosain, P Kalinski, E Van Roey, S Gao, ... Cancer Research 84 (9_Supplement), PO4-25-03-PO4-25-03, 2024 | | 2024 |
